This Article Full Text Full Text (PDF) All Versions of this Article: theoncologist.2009-0213v1 15/1/112    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Google Scholar Articles by Rüttinger, D. Articles by Weber, J. S. PubMed PubMed Citation Articles by Rüttinger, D. Articles by Weber, J. S.

Meeting Report

Immunotherapy of Cancer: Key Findings and Commentary on the Third Tegernsee Conference

^aDepartment of Surgery, Laboratory of Clinical and Experimental Tumor Immunology, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Germany; ^bMicromet AG, Munich, Germany; ^cLaboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA; ^dDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center, and Donald A. Adam Comprehensive Melanoma Research Center, Tampa, Florida, USA

Key Words. Immunotherapy • Conferences • Cancer • Tegernsee

Correspondence: Dominik Rüttinger, M.D., Ph.D., F.A.C.S., Laboratory of Clinical and Experimental Tumor Immunology, Department of Surgery, Grosshadern Medical Center, Ludwig-Maximilians-University Munich, Marchioninistrasse 15, 81377 Munich, Germany. Telephone: 49-089-7095-0; Fax: 49-089-7095-8893; e-mail: dominik.ruettinger{at}med.uni-muenchen.de, Website: http://www.tegernsee-conference.de

Received August 31, 2009; accepted for publication December 4, 2009; first published online in THE ONCOLOGIST Express on January 8, 2010.

Disclosures: Dominik Rüttinger: Employment/leadership position: Micromet AG; Hauke Winter: None; Natasja K. van den Engel: None; Rudolf Hatz: None; Karl-Walter Jauch: None; Bernard A. Fox: Employment/leadership position: UBIVAC; Intellectual property rights/inventor/patent holder: Anti-Cox; Consultant/advisory role: Novartis, Micromet, Neopharm; Research funding/contracted research: Sangamo; Ownership interest: Neopharm, UBIVAC; Jeffrey S. Weber: Intellectual property rights/inventor/patent holder: Medarex; Honoraria: Bristol-Myers Squibb, Medarex; Research funding/contracted research: Bristol-Myers Squibb, Medarex.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Cancer immunotherapy broadly includes active immunization, as in the use of cancer vaccines, passive immunization, such as the use of adoptive cell therapy and antibodies that modulate tumor function, and immunostimulation, using antibodies and small molecules to treat malignancy by activating or unleashing an endogenous immune response against tumor cells. Currently, >100 different monoclonal antibodies are in use or under evaluation for use as therapeutic agents in various malignancies. Active stimulation of the host's immune system holds promise for achieving durable remission of malignant disease and represents a nontoxic method of therapy if tumor-specific effector cells can be selectively targeted. However, no active-specific treatment strategy (i.e., a therapeutic cancer vaccine) has yet found its way into the clinical armamentarium, although several promising recent reports suggest that, for follicular lymphoma, prostate cancer, and melanoma, clinical benefit was shown for the first time in randomized trials with a vaccine approach. Here, we report on the key findings of the Third Tegernsee Conference on Immunotherapy of Cancer (Feldafing, Germany, July 2–4, 2009) and provide short commentaries on data presented at this meeting regarding the future role of cancer vaccines, recent developments in adoptive cellular therapy, ways to improve immunotherapeutic treatment modalities (e.g., by manipulating the tumor microenvironment), and some novel targeted therapies that are well advanced in clinical testing, all of which have implications for future oncology practice.